Moderna, Inc. (MRNA)

Over the past six months, Moderna's stock price has experienced significant fluctuations, with an increase of 83.44% over the last six months and 57.01% over the last six months. As of February 7, 2026, the stock was trading at $41.01, with a 52-week range between $22.28 and $55.20. The clinical performance of next-generation cancer vaccines has boosted the stock price. A Phase 2b clinical trial showed a 49% reduction in the risk of recurrence and death when combining the cancer vaccine with Keytruda in high-risk melanoma patients. Moderna shares had previously fallen after COVID-19 vaccine demand peaked in 2021, but the company reported Q3 2025 EPS of -0.51, outperforming the -2.05 forecast, with revenue of $1.02 billion exceeding expectations, leading to a 7.22% premarket stock increase. U.S. vaccination rates declined by 30%, though Moderna maintained a 42% market share in the COVID vaccine segment. The company reported a net loss of $200 million and held $6.6 billion in cash and investments as of September 30, 2025.

Demand for Moderna's COVID-19 vaccines exhibits seasonality, with seasonal return windows established for products like Spikevax and mNEXSPIKE. The company is building a large seasonal vaccine franchise targeting at-risk populations, with anticipated launches of influenza, flu/COVID combination, and Norovirus vaccines. A decrease in cash, cash equivalents, and investments was primarily driven by seasonal impacts on working capital. While the COVID-19 franchise has historically driven over 95% of Moderna's sales, the company is working to diversify its portfolio to include other seasonal vaccines and therapeutics for oncology and rare diseases.

Moderna, Inc. is an American pharmaceutical and biotechnology company specializing in messenger RNA (mRNA) therapeutics and vaccines. Its core technology uses mRNA to instruct the body's cells to produce an immune response to various diseases. Moderna's major commercial products include the Moderna COVID-19 vaccine (Spikevax) and an RSV vaccine (mResvia). The company has a robust pipeline with 44 treatment and vaccine candidates, 37 of which have entered clinical trials, including potential vaccines for influenza, HIV, and several other viruses, as well as cancer treatments.

Moderna's corporate headquarters is located in Cambridge, Massachusetts, serving as the central hub for its global operations. The company has expanded its commercial presence to 11 countries worldwide, including Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, Switzerland, the UK, and the U.S. Moderna plans to increase its commercial footprint across ten additional markets in Asia-Pacific and Europe. The company has commercial agreements with distributors to supply its COVID-19 vaccine in 45 countries, including partnerships in Latin America, Asia Pacific, and Central Eastern Europe and Israel. Specific office locations outside the U.S. include Melbourne, Paris, Munich, Tokyo, Warsaw, Seoul, Madrid, Basel, and Taipei.

Moderna's brand reputation has seen notable recognition, including being named to Fortune's World's Most Admired Companies list in January 2024. The company has faced scrutiny regarding vaccine pricing and profit margins, raising questions about ethical practices. Moderna is involved in ongoing legal disputes, including patent infringement lawsuits filed by Arbutus Biopharma and GSK plc, as well as cases between Moderna and Pfizer and BioNTech.

Moderna, Inc. has a substantial institutional ownership base, with 1064 institutional owners and shareholders holding a total of 293,755,426 shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Baillie Gifford & Co, and State Street Corp. Mutual funds and ETFs hold 38.53%, and other institutional investors hold 33.12%. Individual insider shareholders held 7.28% of Moderna's outstanding stock shares as of June 2025, with the company's CEO and other executives being top insider shareholders.